nordisk semaglutide Novo Nordisk's shows promise in Phase III CKD trial Novo asks FDA to prevent

Pitolisant in PWS is currently advancing through late-stage development, with Phase III topline data readout expected in 2H 2026

The goal is to help patients use GLP-1 therapy safely and effectively with medical supervision

Some patients may also drink less water or eat less fiber because their appetite is reduced, which can make constipation more likely

It depends on your goals, your biology, your willingness to change habits, and how your body responds when the medication stops

Low-grade metabolic acidosis reduces systemic buffering capacity, increasing reliance on bone, muscle, and connective tissue to neutralize acid loads